Damian Marron
Damian Marron
Chairman of the Board
Close
Damian Marron
Damian Marron
Chairman of the Board

Damian Marron is an experienced non-executive director, corporate advisor and life science executive with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements as well as R&D collaborations, both as an executive and in advisory roles. He has notably specialized in immuno-oncology, cell therapy and orphan diseases. Mr. Marron is currently Non-Executive Chair of the Board at Imophoron Ltd and Cytoseek Ltd, both private, UK start-ups, Non-Executive Director at Bone Therapeutics a clinical stage, regenerative medicine company listed on Euronext and Resolys Bio, a private, late pre-clinical U.S. startup. He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm. Mr. Marron has formerly been chair of the board of directors of PepGen Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA. Mr Marron is a British and Irish citizen, and he resides in France.

Shares
Share options
RSU 141,753
Bente-Lill Romøren
Bente-Lill Romøren
Board member
Close
Bente-Lill Romøren
Bente-Lill Romøren
Board member

Bente-Lill Bjerkelund Romøren is a consultant with 40 years’ experience from national and international management positions in the pharmaceutical industry. She was formerly CEO of Novo Nordisk Scandinavia. Her experience spans senior management, marketing, sales, business development, licensing, market access, public affairs, clinical trials and lifecycle management. Ms. Bjerkelund Romøren has good knowledge of the healthcare system as well as regulations and framework for the pharmaceutical market. She has board member experience from the private and public sector (healthcare). She holds a MSc degree in chemistry from the Norwegian Institute of Technology in Trondheim. Ms. Bjerkelund Romøren is a Norwegian citizen, and resides in Norway.

Shares 35, 577
Share options
RSU 11 361
Diane Mellett
Diane Mellett
Board member
Close
Diane Mellett
Diane Mellett
Board member

Diane Mellett is a consultant to a number of biotech and medical device companies. She has qualified in both US and UK law and advises biotechnology companies in commercial contract and intellectual property matters. She was formerly General Counsel for Cambridge Antibody Technology (CAT) (LSE: NASDAQ) and led the secondary NASDAQ listing of that company as well as serving on the board of directors. During her time at CAT, she led a successful defense of a contractual dispute with Abbott Pharmaceuticals (now Abbvie) covering the company’s major collaboration partnership regarding Humira®, the most successful revenue generating antibody therapy in the pharmaceutical industry to date. Ms. Mellett is a UK citizen, and resides in France.

Shares 102,078
Share options
RSU 115,949
Eva-Lotta Allan
Eva-Lotta Allan
Board member
Close
Eva-Lotta Allan
Eva-Lotta Allan
Board member

Eva-Lotta Allan is an experienced biotechnology deal-maker with over 25 years of business development experience from the biotechnology and life science industry in both private and public companies. She has significant operational and investor relations expertise. Until the end of April 2018, Ms. Allan was Chief Business Officer at Immunocore, an immune-oncology company specializing in the development of soluble T-cell receptor based drugs. Immunocore secured Europe’s largest private life sciences financing in July 2015. Ms. Allan was previously at Ablynx NV, where she served as Chief Business Officer for close to seven years and brought in multiple strategic partnerships. She is the Non-Executive Chairman of C4X Discovery and serves as Non-Executive Director of Crescendo Biologics’ Board and of Aleta Biotherapeutics’ Board. Prior to Ablynx, Ms. Allan served as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals, where she was also a Director of the Board of Vertex Europe. She received her degree in microbiology from the University of Stockholm. Ms. Allan is a Swedish citizen, and resides in the United Kingdom.

Shares 94,859
Share options
RSU 98,539
Robert Burns
Robert Burns
Board member
Close
Robert Burns
Robert Burns
Board member

Robert Burns is an advisor to companies developing immune based therapies in cancer and autoimmune indications. He has been involved for more than 30 years in building biotechnology companies focused on immuno-oncology. Dr. Burns is currently Chairman of Affibody AB in Sweden, a company developing novel therapies in autoimmune and inflammation indications. Dr. Burns was a member of the board of directors of Oncos Therapeutics OY prior to the Company’s acquisition of Targovax Oy. He was previously chairman of the board of directors of Haemostatix Limited before it was acquired by Ergomed plc. He was also previously CEO at 4-Antibody AG, Affitech A/S (NASDAQ/OMX) and Celldex Therapeutics Inc (NASDAQ), each an immuno-oncology vaccine and antibody discovery company. Prior to Celldex Therapeutics, Dr. Burns was Director of Technology Licensing at the Ludwig Institute for Cancer Research, an international independently financed not-for-profit research group focused on cancer vaccines and antibody based cancer immunotherapies. He holds a PhD in Chemistry and is a UK citizen, residing in Oxford, United Kingdom.

Shares 275,454
Share options 21,235
RSU 122,434
Sonia Quaratino
Sonia Quaratino
Board member
Close
Sonia Quaratino
Sonia Quaratino
Board member

Dr Quaratino is an R&D executive with strong experience in clinical development and immunology research, from academia where she was a Professor of Immunology, to large Pharma and Biotech.

Currently, she is also a Non-Executive Director at Ichnos Science, USA, Chair of the Scientific and Clinical Advisory Board at Stipe, Denmark, and member of the SCAB at Anaveon, Switzerland. She covers an Executive role as CMO at Georgiamune, USA. Dr Quaratino was previously CMO at Kymab (UK) from 2017 until its acquisition by Sanofi in 2021. She was Gloabl Clinical Program Leader in Oncology at Novatis (Switzerland), Senior Medical Director in Oncology and Advisor in Immunology at Merck Serono (Germany).

Shares
Share options
RSU 138,178
Raphael Clynes
Raphael Clynes
Board member
Close
Raphael Clynes
Raphael Clynes
Board member

Dr Clynes is an internationally recognized cellular immunologist and medical oncologist. Dr Clynes was on the faculty at the Columbia University where he developed several novel therapeutic approaches in cancer and autoimmunity. Since joining industry in 2014, Dr Clynes has led clinical immunotherapy development, including checkpoint inhibtors and novel CD3 bispecifics, at Bristol Myers Squibb (BMS) and at Xencor, where he is currently VP Translational Biology.

Dr Clynes is an MIT graduate and MSKCC-trained medical oncologist. As a well-recognized expert in clinical immunology, Dr Clynes has extensive prior experience as a contributing member of multiple scientific advisory boards in biopharma and review boards at international research foundations.

Shares
Share options
RSU 115,456

 

Thomas Falck
Thomas Falck
Board member
Close
Thomas Falck
Thomas Falck
Board member

Mr Falck is an experienced CEO, CFO, Board Chair and Non-Executive Director, Venture Capitalist & Growth Investor with demonstrated success in defining and delivering profitable growth while undertaking strategic and organizational change. He has broad experience with Private Equity, Venture Capital, Stock Listed, Family and Government owned entities.

Mr Falck holds an MBA from The Darden School at the University of Virginia and is a graduate of the Norwegian Naval Academy and the Norwegian Defense University College. In addition, Mr Falck has attended Executive Programs at Singularity University and Harvard Business School.

Shares
Share options
RSU 115,456